ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Noxopharm’s Veyonda prevents cytokine storm in Covid-19 trial pharmaceutical-technology
April 26, 2021Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients. -
Noxopharm Files Septic Shock Treatment Patent for Veyonda? americanpharmaceuticalreview
April 15, 2021Australian clinical-stage drug development company Noxopharm Limited announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda? (idronoxil), in blocking the development of septic shock ... -
Noxopharm reports Covid-19 trial programme to commence in Europe pharmaceutical-business-review
July 01, 2020Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.
Pharma Sources Insight January 2025
